← Back to Search

Machine Learning

Machine Learning Monitoring for Clinical Deterioration

N/A

Recruiting

Research Sponsored by AgileMD, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Admitted to an eCART-monitored medical-surgical unit (scoring location)

18 years old

Must not have

Younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up the outcome of covid-19 mortality will be tracked across 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a tool that predicts when hospitalized patients may need intensive care or die, then offers guidance to help care teams intervene.

Who is the study for?

This trial is for adults over 18 years old who are admitted to specific hospital wards where the eCARTv5 monitoring system is used. It's not open to those under 18 or patients in wards without this technology.

What is being tested?

The study tests a machine learning tool, eCARTv5, integrated into hospitals' electronic health records. It predicts which patients might soon need intensive care by analyzing their vital signs and lab results.

What are the potential side effects?

Since this trial involves a diagnostic tool rather than medication, there aren't traditional side effects. However, there may be risks related to data privacy or potential stress from increased monitoring.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am admitted to a unit with eCART monitoring.

Select...

I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am under 18 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ the outcome of covid-19 mortality will be tracked across 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~the outcome of covid-19 mortality will be tracked across 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and the outcome of covid-19 mortality will be tracked across 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Hospital mortality for elevated risk patients

Secondary study objectives

ICU-free days following an eCART elevation

Total hospital length of stay (LOS) for elevated risk patients

Ventilator-free days following an eCART elevation

Other study objectives

COVID-19 Length of Stay (LOS)

COVID-19 Mortality

Sepsis Length of Stay (LOS)

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention ArmExperimental Treatment1 Intervention

Intervention Arm (experimental): eCARTv5 will monitor all adult medical-surgical (ward) patients at hospitals that implement the tool in their EHR. A pre vs. post analysis will be done to compare the impact of the tool at the intervention hospitals.

Group II: Control ArmActive Control1 Intervention

Control Arm (active comparator): hospital sites that do not implement eCARTv5 will be active comparator.

0 / 3Eligibility criteria met